Literature DB >> 16252097

Hypophosphatemic rickets: results of a long-term follow-up.

Maria Helena Vaisbich1, Vera H Koch.   

Abstract

This study reports the benefits and side effects of conventional treatment, phosphate and calcitriol supplementation in patients with heritable hypophosphatemic rickets and a long-term follow-up, median of 60.9 months. The group is composed of 17 patients (ten girls). Sixteen patients presented with bone pain and/or deformities, and in one patient the diagnosis was radiological. All the patients had increased alkaline phosphatase, hypophosphatemia, decreased fractional phosphate tubular reabsorption (TRP) and maximum tubular phosphate reabsorption/glomerular filtration rate ratio (TPO4/GFR). Ten of 17 patients had metabolic acidosis, which was corrected only with the conventional treatment. Potassium citrate was prescribed to the patients who developed hypercalciuria. Excluding one patient with pulmonary dysfunction, the remaining 16 patients were divided into two groups according to the age at treatment onset (T0): group I (GI) > or =4 years (n =9) and GII <4 years (n =7). GI and GII had similar follow-up periods and treatment protocols. Seven out of nine GI patients underwent orthopedic surgery, in contrast to none of GII. Anthropometric data results showed that within each group there is no difference in weight and stature z -score at T0 and at the end of the observation (Tf), but, when both groups are compared, GII shows higher z-score for stature at T0 (p <0.05) and at Tf (p <0.05). Nephrocalcinosis developed in three cases and correlated with hypercalciuria (p <0.001) and dose of calcitriol (p =0.03). In conclusion, higher stature z-score is associated with early treatment. A careful protocol is recommended to detect such complications as nephrocalcinosis. We suggest potassium citrate for patients with hypercalciuria to avoid calcium precipitation.

Entities:  

Mesh:

Year:  2005        PMID: 16252097     DOI: 10.1007/s00467-005-2077-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

Review 1.  Disorders of renal tubular phosphate transport.

Authors:  Harriet S Tenenhouse; Heini Murer
Journal:  J Am Soc Nephrol       Date:  2003-01       Impact factor: 10.121

2.  NPT2a--the key to phosphate homeostasis.

Authors:  Henry M Kronenberg
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

3.  X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone.

Authors:  G S Reusz; G Miltényi; G Stubnya; A Szabó; C Horváth; D J Byrd; F Péter; T Tulassay
Journal:  Pediatr Nephrol       Date:  1997-10       Impact factor: 3.714

4.  Nephrocalcinosis and its relationship to treatment of hereditary rickets.

Authors:  P R Goodyer; J B Kronick; S Jequier; T M Reade; C R Scriver
Journal:  J Pediatr       Date:  1987-11       Impact factor: 4.406

5.  Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets.

Authors:  G I Baroncelli; S Bertelloni; C Ceccarelli; G Saggese
Journal:  J Pediatr       Date:  2001-02       Impact factor: 4.406

Review 6.  Inorganic phosphate homeostasis and the role of dietary phosphorus.

Authors:  Eiji Takeda; Hironori Yamamoto; Kunitaka Nashiki; Tadatoshi Sato; Hidekazu Arai; Yutaka Taketani
Journal:  J Cell Mol Med       Date:  2004 Apr-Jun       Impact factor: 5.310

7.  FGF23 is processed by proprotein convertases but not by PHEX.

Authors:  Anna Benet-Pagès; Bettina Lorenz-Depiereux; Hans Zischka; Kenneth E White; Michael J Econs; Tim M Strom
Journal:  Bone       Date:  2004-08       Impact factor: 4.398

8.  Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet.

Authors:  J Brodehl; A Krause; P F Hoyer
Journal:  Pediatr Nephrol       Date:  1988-04       Impact factor: 3.714

9.  Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets.

Authors:  G S Reusz; K Latta; P F Hoyer; D J Byrd; J H Ehrich; J Brodehl
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

10.  Nephrocalcinosis in X-linked hypophosphataemic rickets: its relationship to treatment, kidney function, and growth.

Authors:  S W Kooh; A Binet; A Daneman
Journal:  Clin Invest Med       Date:  1994-04       Impact factor: 0.825

View more
  4 in total

1.  Dental abnormalities and oral health in patients with Hypophosphatemic rickets.

Authors:  Melissa Almeida Souza; Luiz Alberto Valente Soares Junior; Marcela Alves Dos Santos; Maria Helena Vaisbich
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

2.  Deformity correction in children with hereditary hypophosphatemic rickets.

Authors:  Gert Petje; Roland Meizer; Christof Radler; Nicolas Aigner; Franz Grill
Journal:  Clin Orthop Relat Res       Date:  2008-10-08       Impact factor: 4.176

3.  Nephrocalcinosis and Nephrolithiasis in X-Linked Hypophosphatemic Rickets: Diagnostic Imaging and Risk Factors.

Authors:  Guido de Paula Colares Neto; Fernando Ide Yamauchi; Ronaldo Hueb Baroni; Marco de Andrade Bianchi; Andrea Cavalanti Gomes; Maria Cristina Chammas; Regina Matsunaga Martin
Journal:  J Endocr Soc       Date:  2019-03-25

4.  A novel heterozygous mutation c.680A>G (p. N227S) in SLC34A1 gene leading to autosomal dominant hypophosphatemia: A case report.

Authors:  Xiang Chen; Ying Xie; Shan Wan; Jin Xu; Bei Cai; Yi Zhang; Xijie Yu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.